Bio-Rad Laboratories
BIO
$256.55
-8.41%
Bio-Rad Laboratories is a global developer, manufacturer, and seller of products and solutions for the clinical diagnostics and life sciences markets, operating within the medical devices industry. The company is a well-established, diversified player with a leadership position in digital PCR (dPCR) technology and a significant strategic stake in Sartorius AG. The current investor narrative is heavily influenced by the company's volatile earnings, driven by large non-operating gains and losses related to its Sartorius investment, which creates significant quarter-to-quarter noise and complicates the assessment of its core operational performance.…
BIO
Bio-Rad Laboratories
$256.55
Investment Opinion: Should I buy BIO Today?
Rating & Thesis: Hold. Bio-Rad is a financially strong company trapped in a volatile earnings narrative, making it unsuitable for most investors until core operational consistency improves. The limited analyst coverage shows a cautiously optimistic institutional view (Citigroup/RBC: Buy, Wells Fargo: Equal Weight), but the lack of a consensus price target underscores the analytical challenge.
Supporting Evidence: The valuation sends mixed signals: a low trailing P/E of 10.9x suggests value, but the high forward P/E of 24.7x signals expected earnings decline. The Price/Sales ratio of 3.20x is a more stable metric. Fundamentally, the robust balance sheet (Current Ratio 5.62, D/E 0.205) and solid TTM FCF of $374.6M are clear strengths. However, these are counterbalanced by weak core revenue growth of 3.85% and declining gross margins.
Risks & Conditions: The two biggest risks are 1) continued earnings volatility obscuring operations, and 2) failure to re-accelerate core growth above 5%. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of stable core operating income growth (e.g., >10% YoY) and gross margins stabilize above 51%. It would downgrade to Sell if revenue growth turns negative or if the stock breaks decisively below its recent low of $256.56. Currently, the stock is fairly valued given its mixed profile—neither cheap enough to ignore the flaws nor expensive given its assets.
Sign up to view all
BIO 12-Month Price Forecast
Bio-Rad presents a classic 'good company, challenging stock' scenario. Its superb balance sheet and cash flow are fundamentally attractive, but they are entirely overshadowed by the unreliability of its earnings. The 60% base case probability reflects the expectation that this frustrating dynamic persists. The stance is neutral due to this stalemate; the stock lacks a clear catalyst for a breakout but is also unlikely to collapse given its financial backbone. An upgrade to bullish would require clear evidence that management can stabilize core earnings growth. A downgrade to bearish would be triggered by a breakdown of technical support at $256, signaling a loss of faith in the asset value story.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Rad Laboratories's 12-month outlook, with a consensus price target around $333.52 and implied upside of +30.0% versus the current price.
Average Target
$333.52
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$205 - $334
Analyst target range
Analyst coverage for Bio-Rad is limited, with only one analyst providing estimates according to the provided data, indicating insufficient coverage for a robust consensus view. The single analyst estimates an average EPS of $14.30 for the upcoming period, with revenue estimated at $2.94 billion, but no consensus price target or recommendation distribution is available. The implications of minimal analyst coverage are significant: it typically reflects a smaller institutional following, which can lead to higher volatility, less efficient price discovery, and a greater reliance on company-specific events rather than broad analyst sentiment. The available institutional ratings from recent months show a stable pattern with firms like Citigroup and RBC Capital maintaining 'Buy' or 'Outperform' ratings, while Wells Fargo has consistently held an 'Equal Weight' rating, suggesting a cautiously optimistic view among the few covering firms.
Bulls vs Bears: BIO Investment Factors
The investment thesis for Bio-Rad is characterized by a stark tension between its exceptional financial fortress and its deeply flawed, volatile earnings profile. The bear case currently holds stronger evidence due to the stock's deteriorating price action, inconsistent core growth, and the overwhelming noise in financial results that obscures true operational health. The single most important factor in the investment debate is the resolution of earnings volatility: if the company can demonstrate stable, growing core profits independent of its Sartorius stake, the compelling balance sheet and cash flow would support a re-rating. Until then, the stock is likely to remain a 'show me' story, punished for its unpredictability despite its underlying strengths.
Bullish
- Strong Balance Sheet & Liquidity: The company has a fortress-like balance sheet with a debt-to-equity ratio of only 0.205 and a current ratio of 5.62, indicating minimal financial risk and ample liquidity to weather downturns or fund strategic initiatives. This financial strength is a key differentiator in the volatile healthcare sector.
- Solid Free Cash Flow Generation: Bio-Rad generates robust free cash flow, with TTM FCF of $374.6 million, providing a reliable internal funding source for operations and growth. This consistent cash generation supports the company's stability and reduces reliance on external capital markets.
- Leadership in High-Growth dPCR Tech: The company holds a leadership position in digital PCR (dPCR) technology, a key growth area within the life sciences segment. This technological edge provides a competitive moat and positions BIO to benefit from the expanding genomics and precision medicine markets.
- Valuable Strategic Stake in Sartorius: Bio-Rad's approximately 33% ownership stake in Sartorius AG represents a significant, non-core asset valued in the billions. This stake provides a substantial financial backstop and potential source of future capital, though it also introduces earnings volatility.
Bearish
- Extreme Earnings Volatility: Quarterly net income is wildly erratic due to non-operating gains/losses from the Sartorius stake, swinging from a $720M profit in Q4 2025 to a $341.9M loss in Q3 2025. This makes assessing core operational performance and forecasting earnings nearly impossible, creating significant uncertainty for investors.
- Weak & Inconsistent Core Growth: Core revenue growth is modest and inconsistent, with Q4 2025 revenue of $693.2M representing only 3.85% YoY growth and showing sequential volatility. The company's mature Clinical Diagnostics segment (60% of sales) likely acts as a drag on overall growth momentum.
- Core Margin Compression: The company's gross margin declined from 52.6% in Q3 2025 to 49.8% in Q4 2025, indicating pressure on core operational profitability. The underlying operating margin of 10.47% is modest for a healthcare technology company, suggesting limited pricing power or rising costs.
- Pronounced Technical Downtrend: The stock is in a clear downtrend, down 8.28% over 3 months and 8.35% over 6 months, and is trading 18.4% below its 52-week high. The recent sharp drop to $256.56 on Feb 13, 2026, signals a breakdown in price support and negative investor sentiment.
BIO Technical Analysis
The stock is in a pronounced downtrend, having declined 8.28% over the past three months and 8.35% over the past six months, despite a positive 14.04% gain over the past year. As of the latest close of $279.99, the stock is trading at approximately 81.6% of its 52-week range (between $211.43 and $343.12), indicating it is closer to the high end but has retreated significantly from the peak, suggesting the prior uptrend has lost momentum and the stock is consolidating at a lower level. Recent momentum is negative, with the stock down 7.14% over the past month, which diverges sharply from its positive 1-year trend and signals a significant short-term pullback; this is further evidenced by its relative strength versus the SPY, as the stock's 1-month relative strength of +4.21% indicates it has outperformed the market's 4.28% decline, but this is a function of a less severe drop rather than positive momentum. Key technical support is at the 52-week low of $211.43, while resistance is at the 52-week high of $343.12; a breakdown below the recent low of $256.56 (from February 13, 2026) would signal a continuation of the downtrend, while a recovery above the $300 level is needed to stabilize the price action. The stock's beta of 1.158 indicates it is approximately 16% more volatile than the broader market, which is a consideration for risk management given its current trend.
Beta
—
—
Max Drawdown
-24.5%
Largest decline past year
52-Week Range
$211-$343
Price range past year
Annual Return
+6.7%
Cumulative gain past year
| Period | BIO Return | S&P 500 |
|---|---|---|
| 1m | -7.8% | +10.0% |
| 3m | -12.6% | +4.1% |
| 6m | -19.7% | +5.7% |
| 1y | +6.7% | +29.0% |
| ytd | -16.0% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIO Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $693.2 million representing a 3.85% year-over-year increase; however, the multi-quarter trend is inconsistent, with revenue in the prior Q3 2025 at $653.0 million, indicating some sequential volatility. The Clinical Diagnostics segment ($425.3 million) is the larger revenue driver compared to Life Science ($267.9 million), but specific growth rates by segment are not available to determine the primary growth engine. Profitability is highly erratic due to significant non-operating items; while Q4 2025 net income was a substantial $720 million, this was preceded by a net loss of $341.9 million in Q3 2025, and the gross margin of 49.8% in Q4 is down from 52.6% in Q3, indicating some margin compression in the core business. The company's net margin of 29.42% (from valuation data) is inflated by non-recurring gains, masking the underlying operating margin of just 10.47%, which is more indicative of its core operational profitability. The balance sheet is exceptionally strong with a robust current ratio of 5.62 and a low debt-to-equity ratio of 0.205, indicating minimal financial leverage and high liquidity. The company generates solid free cash flow, with TTM free cash flow of $374.6 million, providing ample internal funding for operations and growth initiatives; the return on equity of 10.20% is reasonable, though it is heavily influenced by the volatile net income figures.
Quarterly Revenue
$693200000.0B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.49%
Latest Quarter
Free Cash Flow
$374600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIO Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 10.87x, while the forward P/E is 24.70x; this significant gap implies the market expects a substantial normalization and decline in earnings from the elevated Q4 2025 level, aligning with the volatile income statement. Compared to industry averages, the stock's trailing P/E of 10.87x and forward P/E of 24.70x cannot be directly contextualized as specific sector average multiples are not provided in the data; however, the Price/Sales ratio of 3.20x and EV/Sales of 2.87x offer alternative cross-sectional measures. Historically, the stock's own trailing P/E has been extremely volatile, ranging from deeply negative figures to over 50x in recent quarters; the current trailing P/E of 10.87x is below the historical average seen in many prior periods (e.g., 26.58x in Q1 2025, 6.65x in Q4 2023), suggesting the market may be applying a discounted multiple due to the earnings volatility and uncertainty surrounding core operations.
PE
10.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The paramount risk is extreme earnings volatility driven by non-operating items related to the Sartorius investment, which caused a $1.06 billion swing in net income between Q3 and Q4 2025. This volatility complicates valuation, erodes investor confidence, and masks the underlying operational margin of just 10.47%. While the balance sheet is strong (D/E 0.205), the core business exhibits modest growth (3.85% YoY in Q4) and recent gross margin compression (down 280 bps sequentially), indicating potential competitive or cost pressures in its mature diagnostics segment.
Market & Competitive Risks: The stock trades at a forward P/E of 24.7x, a significant premium to its trailing P/E of 10.9x, implying the market expects earnings to normalize at a lower level. This creates valuation compression risk if core growth fails to accelerate. With a beta of 1.158, BIO is 16% more volatile than the market, amplifying downside moves during sector rotations away from healthcare or growth stocks. Limited analyst coverage (only one providing estimates) exacerbates liquidity and price discovery risks, making the stock more susceptible to sharp moves on company-specific news.
Worst-Case Scenario: The worst-case scenario involves a sustained downturn in the bioprocessing market hurting Sartorius's value, triggering consecutive quarters of large non-operating losses that overwhelm BIO's core profits. Concurrently, margin compression in the core business accelerates due to pricing pressure, and growth stagnates. This could lead to a re-rating to a distressed multiple, driving the stock toward its 52-week low of $211.43. From the current price of ~$280, this represents a realistic downside of approximately -25%.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: Non-operating gains/losses from the Sartorius stake create unpredictable quarterly swings (e.g., $720M profit to $341.9M loss), making the stock un-investable for many. 2) Growth & Margin Risk: Core revenue growth is modest (3.85%) and gross margins are compressing (down to 49.8% in Q4). 3) Liquidity & Coverage Risk: With only one analyst providing estimates, the stock suffers from lower institutional following and potentially inefficient price discovery. 4) Technical Risk: The stock is in a downtrend, down over 8% in six months, and a break below $256 could trigger further selling.
The 12-month forecast is a range of scenarios with a neutral base case. The Bull Case (25% probability) targets $330-$343, requiring stable core earnings and dPCR-driven growth. The Base Case (60% probability) targets $270-$300, expecting continued modest growth and earnings noise to keep the stock range-bound. The Bear Case (15% probability) targets $211-$256, involving a downturn in the Sartorius stake and further margin pressure. The base case is most likely, anchored by the expectation that the current challenging dynamic—strong assets obscured by volatile profits—persists.
BIO's valuation is contradictory and context-dependent. Its trailing P/E of 10.9x appears deeply undervalued, but this is an artifact of a one-time gain. The forward P/E of 24.7x suggests the market expects much lower future earnings. A cleaner metric is the Price/Sales ratio of 3.20x. Given the company's low growth (3.85% YoY) and earnings volatility, this multiple seems fairly valued relative to its mixed profile. The market is not paying a premium for growth but is also not fully discounting the company's valuable assets and financial strength.
BIO is not a straightforward 'good buy' for most investors. For those seeking stable earnings and predictable growth, it is a poor choice due to its extreme quarterly volatility. However, for a specialized, patient investor, its rock-solid balance sheet (D/E 0.205), strong cash flow ($374.6M TTM FCF), and valuable Sartorius stake provide a margin of safety. The current Hold rating reflects this dichotomy—it could become a good buy if core operational performance stabilizes, but that is not the current base case.
BIO is unsuitable for short-term trading due to its high beta (1.158) and unpredictable quarterly earnings, which can cause violent price swings around reports. It is only appropriate for long-term investors with a minimum 3-5 year horizon who can look past the quarterly noise. This extended timeframe allows for the potential realization of value from the Sartorius stake, maturation of the dPCR business, or a corporate strategic review. The lack of a dividend further reinforces its role as a long-term capital appreciation story, albeit a volatile one.